scholarly journals Humoral response of pregnant sows to foot and mouth disease vaccination

1986 ◽  
Vol 96 (3) ◽  
pp. 501-511 ◽  
Author(s):  
M. J. Francis ◽  
L. Black

SUMMARYFour groups of sows were inoculated, either once or twice, with O1BFS 1860 foot and mouth disease oil-emulsion vaccine during pregnancy and samples of serum. for analysis, were collected at intervals for > 300 days.The pregnant sows responded well to vaccination regardless of their state of gestation. Single vaccination produced protective levels of antibody (> 1·53 log10SN50) in 3 out of 4 sows while double vaccination produced protective levels in all 6 sows tested. Anti-FMD IgM antibodies could be detected for 40–60 days after vaccination or revaccination. Anti-FMD IgG antibodies appeared within 10 days of vaccination and persisted, in each sow, for the duration of the study. The anti-FMD IgA response observed was less easy to characterize due to significant animal to animal variation. Although there was no evidence of a fall in the neutralizing antibody titres over one year post vaccination the anti-FMD IgG antibody population did show signs of a change in its heterogenity and avidity.

1984 ◽  
Vol 93 (1) ◽  
pp. 123-131 ◽  
Author(s):  
M. J. Francis ◽  
L. Black

SUMMARYFour groups of pregnant sows were inoculated with type O1 foot and mouth disease (FMD) oil emulsion vaccine at various times before farrowing and samples of the sow's serum, colostrum and milk, and piglet's serum, collected during the first week after farrowing, were analysed for FMD virus neutralizing activity.No FMD neutralizing antibodies were detectable in the piglets serum at birth but they were present 1·5 h after suckling and peak titres were reached 1–3 days later. There was no significant difference between the antibody titres of colostrum samples collected from different teats at farrowing. However, similar samples collected 3 days later showed significant (P < 0·005) fore to hind variation. The principal FMD virus neutralizing antibody class present in the sow's serum at farrowing and in their 3-day-old piglets was governed by the inoculation schedule employed. When the last vaccinations were given ≃ 30 days before farrowing (dbf) the predominant FMD virus neutralizing class was IgG. However, when the sows were vaccinated only ≃ 12 dbf the predominant class was IgM. A significant correlation was observed between the sow's serum titres and colostrum titres at farrowing (r = 0·90), and also between sows colostrum titres at farrowing and their 3-day-old piglets serum titres (r = 0·99).


1978 ◽  
Vol 80 (1) ◽  
pp. 31-42 ◽  
Author(s):  
J. C. Booth ◽  
M. M. Rweyemamu ◽  
T. W. F. Pay

SUMMARYTwo-dimensional quantal microneutralization tests on foot-and-mouth disease viruses, in which neutralizing antibody activity was titrated against a serial range of virus doses, demonstrated a variety of dose-response curves some of which were rectilinear, others clearly curvilinear. Moreover, in the case of the non-linear responses obtained with some antisera, the shape of the curve was such that antibody titres recorded with doses of virus ranging from 103–105TCD 50 were closely similar. Studies were carried out on the effect of varying the conditions of the test on the shape of the dose-response curve: significant differences were obtained after treatment of the antiserum–virus mixtures with anti-species globulin, and when the test was assayed in cells of differing susceptibility to infection.


Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1091
Author(s):  
Young-Hoon Ahn ◽  
W. A. Gayan Chathuranga ◽  
Young-Jung Shim ◽  
D. K. Haluwana ◽  
Eun-Hee Kim ◽  
...  

Foot-and-mouth disease (FMD) is a notifiable contagious disease of cloven-hoofed mammals. A high potency vaccine that stimulates the host immune response is the foremost strategy used to prevent disease persistence in endemic regions. FMD vaccines comprise inactivated virus antigens whose immunogenicity is potentiated by immunogenic adjuvants. Oil-based adjuvants have clear advantages over traditional adjuvant vaccines; however, there is potential to develop novel adjuvants to increase the potency of FMD vaccines. Thus, we aimed to evaluate the efficacy of a novel water-in-oil emulsion, called CAvant®SOE, as a novel vaccine adjuvant for use with inactivated FMD vaccines. In this study, we found that inactivated A22 Iraq virus plus CAvant®SOE (iA22 Iraq-CAvant®SOE) induced effective antigen-specific humoral (IgG, IgG1, and IgG2a) and cell-mediated immune responses (IFN-γ and IL-4) in mice. Immunization of pigs with a single dose of iA22 Iraq-CAvant®SOE also elicited effective protection, with no detectable clinical symptoms against challenge with heterologous A/SKR/GP/2018 FMDV. Levels of protection are strongly in line with vaccine-induced neutralizing antibody titers. Collectively, these results indicate that CAvant®SOE-adjuvanted vaccine is a promising candidate for control of FMD in pigs.


1972 ◽  
Vol 23 (3) ◽  
pp. 159
Author(s):  
Χ. ΠΑΠΠΟΥΣ ◽  
Δ. ΜΠΡΟΒΑΣ ◽  
Ι. ΚΑΡΑΒΑΛΑΚΗΣ ◽  
Irakleitos Souyioultzoglou

4 batches of Foot - and - Mouth Disease (FMD) vaccine were assayed in adult goats, from local breedings, serologically positive for Brucella. These goats were to be slaughtered, in accordance with an eradication program. The viremia was checked by using the plaque forming unit (PFU) and the cytopathic effect methods, every 24 hours for 3 days post—inoculation and it has been found that it is variable both in intensity and duration. In the controls the viremia was detected in 4/5 to 5/5 of the animals whereas in the vaccinated animals it dependent on the dose of vaccine and on virus units (104 to 105 ) used, for the infection. The neutralizing antibody titres after vaccination were generally lower than those observed in cattle and sheep and they varied significantly among the animals vaccinated with the same dose. This is in accordance with the findings of a preliminary work where the titres were also low and they were then attributed to the young age of the animals used. The titres were about the same in the groups vaccinated with undiluted or diluted 1/4 vaccine and lower in those vaccinated with 1/16 of the normal dose. The revaccination carried out 3 weeks after the first vaccination increases the antibody titre as well as the resistance of animals to challenge. It was observed that an increase of the antibody titres resulted in a decrease of the percentage of animals positive to viremia but this percentage was still significant even in goats with high antibody titres.As regards to the generalization of the disease it was not so frequent when the infection was made with 104 to 105 DL^ FMD virus and it mostly affected the animals partially, on 1, 2 or 3 feet. With the use of higher doses of virus (10-6 · 50) the resistance of the animals appeared to be overcome by the infection. Sometimes, despite the high titres (1,87 and 1,95) of antibodies, viremia occured whereas in some animals with generalized lesions the viremia was not detected. This last fact may be due to the temporariness of the viremia or its eventual late appearance. As a conclusion we consider that viremia detection may be used for estimating the potency of FMD vaccine in goats, when the animals are infected with 104 to 105 DL5 0 FMD virus.The generalization of the disease must also be taken into account in cases that viremia is not detected. So the 4 vaccine batches, of a protective dose 50% for guinea pigs {0.25, (0.14, 0.12 and 0.48 ml, when tested on goats, their protective dose 50% was respectively 0.50, <1 , 1.25 and 0.47ml. If both viremia and generalization are taken into account, then the protective dose 50% for goats were respectively 0.50, <1 , 1.25 and 0.96 ml.


npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Hyundong Jo ◽  
Bong Yoon Kim ◽  
So Hui Park ◽  
Hyun Mi Kim ◽  
Sung Ho Shin ◽  
...  

AbstractCurrent foot-and-mouth disease (FMD) vaccines have significant limitations, including side effects due to oil emulsions at the vaccination site, a narrow spectrum of protective efficacy, and incomplete host defenses mediated by humoral immunity alone. To overcome these limitations, new FMD vaccines must ensure improved safety with non-oil-based adjuvants, a broad spectrum of host defenses within/between serotypes, and the simultaneous induction of cellular and humoral immunity. We designed a novel, immune-potent, recombinant protein rpHSP70-AD that induces robust cellular immunity and elicits a broad spectrum of host defenses against FMD virus (FMDV) infections. We demonstrated that an oil emulsion-free vaccine containing rpHSP70-AD mediates early, mid-term, and long-term immunity and drives potent host protection against FMDV type O and A, suggesting its potential as an FMD vaccine adjuvant in mice and pigs. These results suggest a key strategy for establishing next-generation FMD vaccines, including novel adjuvants.


Sign in / Sign up

Export Citation Format

Share Document